Trial · NCT03720366
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
NCT03720366, Phase 1, Completed, Celgene
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients. Trials, record NCT03720366. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03720366
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
- NCT number
- NCT03720366
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 40 participants, actual
- Lead sponsor
- Celgene
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- enasidenib, Arm 1 probes, Arm 2 Probes, Arm 3 probes
- First posted
- 2018-10-25
- Last updated
- 2024-02-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pharmacokinetics - AUC0-30 | Up to approximately 29 days | Area under the probe plasma concentration-time curve calculated from time zero to 30 hours |
| Primary | Pharmacokinetics - Cmax | Up to approximately 29 days | Observed maximum probe plasma concentration |
| Secondary | Pharmacokinetics - AUC0-∞ | Up to approximately 29 days | Area under the probe plasma concentration time curve from time zero to infinity |
| Secondary | Pharmacokinetics -t1/2,z | Up to approximately 29 days | Terminal elimination half life for the probes |
| Secondary | Pharmacokinetics - CL/F | Up to approximately 29 days | Apparent clearance of probes from plasma |
| Secondary | Pharmacokinetics - Vz/F | Up to approximately 29 days | Apparent total volume of distribution of the probes, based on the terminal phase |
| Secondary | Complete Response Rate | Up to approximately 28 months | Measurement of tumor size reduction by a predefined amount over the defined time period |
| Secondary | Adverse Events (AEs) | Up to approximately 28 months | Number of participants with adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03720366
GET https://conductscience.org/api/trials/v1/NCT03720366/registered